K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, K2 Capital Acquisition Corporation Class A Ordinary Share (NASDAQ: KTWO) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $10.12 (+0.30% 1D, market cap $202.8M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, KTWO ranks #307 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), KTWO carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PDEX (Pro-Dex Inc.) holds a D grade (51/100 RQD, P/E 22.2x, ROIC 23.2%, cap $199.2M) and UTMD (Utah Medical Products Inc.) posts a C grade (63/100 RQD, P/E N/A, ROIC 26.9%, cap $212.7M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).
Per KTWO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002086524), K2 Capital Acquisition Corporation Class A Ordinary Share generated $0 in revenue, $0 in net income, and $0 in free cash flow against $754.7K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
FRED Regime × Technicals: 99% of 52W Range • RSI-14 at 49.4 (NEUTRAL RANGE)
Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)
While KTWO currently carries a cautious 53/100 (D+) rating due to Whale & Options Positioning (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.09) and Max Pain ($10.63) forces dealer call-delta covering toward $11.67.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) advanced +0.30% to $10.12, trading at 99% of its 52-week range ($9.84 – $10.12). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Vancouver, British Columbia, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Deep Sea Minerals Corp. (CSE: SEAS) (OTCQB: DSEAF) (FSE: X450) ("Deep Sea Minerals" or the "Company"), a seabed mineral exploration and development company f
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on KTWO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for KTWO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) ranks #307 by composite RQD confidence (53/100, grade D+) and #577 by equity capitalization ($202.8M). Within this direct 5-issuer industry benchmark cohort, PDEX leads on earnings valuation at 22.2x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. UTMD currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with KTWO at 53/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| KTWO
ACTIVE
K2 Capital Acquisition Corporation Class A Ordinary Share | D+ | 53/100 | — | — | — | +0.30% | $202.8M | Benchmark Subject |
| PDEX Pro-Dex Inc. | D | 51/100 | 22.2x | 29.3% | 23.2% | -2.52% | $199.2M | /pdex-vs-ktwo → |
| UTMD Utah Medical Products Inc. | C | 63/100 | — | 57.1% | 26.9% | -2.96% | $212.7M | /utmd-vs-ktwo → |
| PROF Profound Medical Corp. | D | 47/100 | — | 70.8% | -35.0% | +1.38% | $214.1M | /prof-vs-ktwo → |
| STIM Neuronetics Inc. | E | 31/100 | — | 48.5% | -35.0% | +5.31% | $181.3M | /stim-vs-ktwo → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, KTWO closed FY2025 with $754.7K in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $754.7K | — |
As of 2026-11-01, K2 Capital Acquisition Corporation Class A Ordinary Share (NASDAQ: KTWO) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $10.12 (+0.30% 1D, market cap $202.8M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, KTWO ranks #307 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), KTWO carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PDEX (Pro-Dex Inc.) holds a D grade (51/100 RQD, P/E 22.2x, ROIC 23.2%, cap $199.2M) and UTMD (Utah Medical Products Inc.) posts a C grade (63/100 RQD, P/E N/A, ROIC 26.9%, cap $212.7M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).
Per KTWO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002086524), K2 Capital Acquisition Corporation Class A Ordinary Share generated $0 in revenue, $0 in net income, and $0 in free cash flow against $754.7K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
KTWO last traded at $10.12 (+0.30% on volume of 164 shares), positioning the stock +0.30% above its 50-day simple moving average ($10.09) and +1.40% above its 200-day simple moving average ($9.98). Across its 52-week range of $9.84 to $10.12, KTWO sits at the 100.0% percentile with a 14-day RSI of 49.4 (NEUTRAL RANGE) and an implied next-earnings move of ±1.8% ($9.94 to $10.30).
Why KTWO Stock advanced +0.30% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.